TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28786987
Drug: Discontinuation due
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation due to adverse events
Study: 28787430
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and Docetaxel (G/D) window therapy
Study: 28787430
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and Docetaxel (G/D)
Study: 28789851
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine (4th dose)
Study: 28789851
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine (3 doses)
Study: 28790169
Drug: 6-month follow-up
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month follow-up understanding of warfarin and direct oral anticoagulants (DOACs)
Study: 28790169
Drug: Understanding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Understanding of oral anticoagulant benefits at diagnosis
Study: 28790169
Drug: Overall understanding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall understanding of AF treatment at 6 months
Study: 28791297
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g omega-3 (OMACOR) daily
Study: 28791628
Drug: Surgical approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical approach using mitomycin C (MMC) at a dose of 25 mg/m
Study: 28791628
Drug: Percutaneous approach
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous approach using mitomycin C (MMC) at a dose of 25 mg/m
Study: 28791698
Drug: Fenoterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (180 µg) administered to OCT1-deficient individuals (n=5)
Study: 28794078
Drug: SB4 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB4 (50 mg weekly subcutaneous administration)
Study: 28794078
Drug: ETN (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN (50 mg weekly subcutaneous administration)
Study: 28794136
Drug: Preoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative serum neutrophil gelatinase-associated lipocalin (sNGAL) levels in the last tertile (>220 ng/L)
Study: 28794208
Drug: Increasing amounts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing amounts of chicken intake (from 88 to 290 g/d) over 3 weeks
Study: 28794898
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination pill
Study: 28795383
Drug: Integrated Imaginative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Imaginative Distention (IID) therapy, delivered as eight weekly training group sessions by a skilled psychotherapist.
Study: 28796812
Drug: ONCOS-102 (Ad5/3-D24-GM-CSF)
Normalized name: ONCOSTATIN K
DrugBank: ONCOS-102 (DB17274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONCOS-102 (Ad5/3-D24-GM-CSF) administered by intracardial, intraperitoneal or subcutaneous injections
Study: 28796812
Drug: Cyclophosphamide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide administered intraperitoneally twice a week
Study: 28796812
Drug: NaCl solution
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaCl solution administered to control group
Study: 28797193
Drug: Venetoclax monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax monotherapy (800-1200 mg)
Study: 28797782
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy for cGVHD
Study: 28798986
Drug: Tasquinimod (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasquinimod (0.5 mg/day for at least 2 weeks, increased to 1 mg/day)
Study: 28800628
Drug: Sotalol 80mg
Normalized name: sotalol 80 MG
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sotalol 80mg oral dose
Study: 28801186
Drug: Adjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant temozolomide (12 4-week cycles of 150-200 mg/m²) with radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy)
Study: 28801477
Drug: Impaired renal
Normalized name: nut.tx.impaired renal fxn,soy ORAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired renal function (eCCl <60 mL/min)
Study: 28801477
Drug: Both T2DM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both T2DM and eCCl <60 mL/min
Study: 28802168
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine (30µg)
Study: 28802168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HBV vaccine)
Study: 28802255
Drug: Sym015, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym015, an antibody mixture composed of two humanized IgG
Study: 28803122
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet of rosuvastatin 20 mg/ezetimibe 10 mg
Study: 28803122
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of rosuvastatin 20 mg and ezetimibe 10 mg
Study: 28803675
Drug: Fitness center
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitness center intervention (structured thrice weekly aerobic and resistance exercise program, supervised for the first 6 months)
Study: 28804454
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy using a novel rehabilitation device
Study: 28805662
Drug: CD30-specific chimeric
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts) infused at doses of 0.2 × 10^8 to 2 × 10^8 CD30.CAR-Ts/m2
Study: 28805662
Drug: CD30-specific chimeric
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts)
Study: 28808360
Drug: Bemiparin (3500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemiparin (3500 IU anti-factor Xa, subcutaneous injection once daily)
Study: 28808360
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg, subcutaneous injection once daily)
Study: 28808443
Drug: Lisinopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (ACE inhibitor) for 1 week
Study: 28808480
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy with modified EPIC regimen (etoposide, prednisolone, ifosfamide, cisplatin), median 3 cycles (range 1-6)
Study: 28810177
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotic medications (SGAs)
Study: 28810837
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg + Bevacizumab 7.5 mg/kg (DL1)
Study: 28810837
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg + Bevacizumab 7.5 mg/kg (DL2)
Study: 28810837
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg + Bevacizumab 10 mg/kg (DL3)
Study: 28810837
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg + Bevacizumab 10 mg/kg (DL4)
Study: 28810837
Drug: Pazopanib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (400 mg and 600 mg) pharmacokinetics
Study: 28810904
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (AAD) - beta blockers (80.9% in previously diagnosed AF, 71.0% in newly diagnosed AF), calcium channel antagonists (24.0% in newly diagnosed AF).
Study: 28810904
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (AAD) - class I (11.4%) and class III (9.1%) AADs.
Study: 28810904
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers as rate control therapy.
Study: 28810925
Drug: Surgical IPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical IPP with melphalan 30 mg/m²
Study: 28810925
Drug: Percutaneous IPP
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous IPP with melphalan 30 mg/m²
Study: 28813164
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity.
Study: 28814281
Drug: New generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generation hormone-therapy (NGHT)
Study: 28814281
Drug: First generation
Normalized name: First generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First generation androgen deprivation therapy (Control)
Study: 28814336
Drug: Shared injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shared injection drug solution
Study: 28814336
Drug: Received used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received used drug injection equipment
Study: 28814336
Drug: Shared solutions
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shared solutions
Study: 28814336
Drug: Unsafe injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsafe injection risk
Study: 28814336
Drug: Injection risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection risk behaviour
Study: 28814412
Drug: Aflibercept 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2.0 mg intravitreal injections
Study: 29556416
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W)
Study: 28814660
Drug: ERT monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT monotherapy
Study: 28814674
Drug: Rilonacept (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (loading dose 4.4 mg/kg, followed by 2.2 mg/kg once weekly for 12 months, with dose escalation allowed)
Study: 28815645
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg/day orally on days 1-21 every 4 weeks
Study: 28817190
Drug: Filanesib (1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filanesib (1.50 mg/m²) single agent
Study: 28817190
Drug: Filanesib (1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filanesib (1.50 mg/m²) plus dexamethasone (40 mg/week)
Study: 28817727
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including 2 mg/kg per day of prednisone equivalent
Study: 28817753
Drug: Durvalumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab, 10 mg/kg every 2 weeks for up to 12 months
Study: 28817753
Drug: Durvalumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab, 10 mg/kg every 2 weeks
Study: 28818050
Drug: Probiotic administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic administration with Bifidobacterium animalis subsp. lactis (BB-12®) and Lactobacillus rhamnosus (LGG®) for 6 months
Study: 28818061
Drug: Longitudinal mean
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal mean deviation (MD) and visual acuity (VA) from the Ocular Hypertension Treatment Study (OHTS)
Study: 28818546
Drug: Glecaprevir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir (300 mg) plus Pibrentasvir (120 mg) once daily for 12 weeks
Study: 28819385
Drug: Kanglaite Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanglaite Injection (KLTi) plus Gemcitabine
Study: 28819927
Drug: Delayed-release prednisone
Normalized name: prednisone Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release prednisone (DR-prednisone)
Study: 28819927
Drug: Immediate-release prednisone
Normalized name: prednisone Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release prednisone (IR-prednisone)
Study: 28819932
Drug: Twice-daily (BID)
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily (BID) dosing of 0.075% bromfenac in DuraSite
Study: 28819932
Drug: Once-daily (QD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (QD) dosing of 0.075% bromfenac in DuraSite
Study: 28820321
Drug: Whole-mouth ultrasonic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole-mouth ultrasonic debridement, scaling and root planing, and a 7-day prescription of amoxicillin and metronidazole
Study: 28822957
Drug: 67 mcg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67 mcg/kg/day of recombinant human growth hormone (rhGH) for 2 years
Study: 28823829
Drug: Strict-normal thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict-normal thyroid function (plasma TSH level 0.4 to 2.5 mIU/L)
Study: 28823829
Drug: Subclinical hypothyroidism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subclinical hypothyroidism (plasma TSH above 4.5 mIU/L)
Study: 28823829
Drug: Low-normal thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-normal thyroid function (plasma TSH level 2.5 to 4.5 mIU/L)
Study: 28824369
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg daily)
Study: 28826066
Drug: Acceptance-based interoceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based interoceptive exposure treatment
Study: 28827212
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A), delivered as 9 sessions of 55 minutes each by advanced doctoral and masters students in clinical psychology.
Study: 28829523
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient-controlled analgesia (IV-PCA)
Study: 28830854
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation methods (infusion rate table)
Study: 28834619
Drug: High-dose benazepril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose benazepril (mean 69 mg/day, range 40-80)
Study: 28834619
Drug: High-dose valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valsartan (mean 526 mg/day, range 320-640)
Study: 28834619
Drug: High-dose valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valsartan
Study: 28834619
Drug: Low-dose benazepril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose benazepril (20 mg/day)
Study: 28834619
Drug: Low-dose valsartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valsartan (160 mg/day)
Study: 28834619
Drug: Extended-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metoprolol (mean 152 mg/day, range 23.75-190)
Study: 28835355
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 at a dose of 2×10^8 CFU
Study: 28837404
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in cancer survivors
Study: 28837404
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in general population
Study: 28837404
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in adolescent survivors (ages 13 to 17 years)
Study: 28837404
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in adolescent peers (ages 13 to 17 years)
Study: 28837404
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in young adult survivors (ages 18 to 26 years)
Study: 28837404
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in young adult peers (ages 18 to 26 years)
Study: 28837404
Drug: Predictors of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictors of noninitiation - endorsement of vaccine-related barriers
Study: 28837405
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks up to 2 years or until disease progression or unacceptable toxicity
Study: 28838044
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation with vitamin-K antagonists or non-VKA oral anticoagulants
Study: 28838044
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral anticoagulation
Study: 28838858
Drug: Concurrent cartilage
Normalized name: SHARK CARTILAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cartilage thickness change (Y2→Y4)
Study: 28838886
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the 12-week physical activity program with weekly group sessions and an individualized, progressive, home-based exercise program.
Study: 28840147
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg intramuscularly weekly for 8 weeks)
Study: 28840147
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline intramuscularly weekly for 8 weeks)
Study: 31809241
Drug: Osimertinib 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 160 mg once daily
Study: 28841389
Drug: Osimertinib across
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib across doses
Study: 28842294
Drug: Preoperative intra-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intra-platelet serotonin (IP5-HT) levels >134ng/ml
Study: 28842294
Drug: Preoperative intra-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intra-platelet serotonin (IP5-HT) levels <73ng/ml
Study: 31471185
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor treatment
Study: 28843382
Drug: Air infusion
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air infusion into saline during office hysteroscopy
Study: 28843918
Drug: Cariprazine 3-12
Normalized name: cariprazine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3-12 mg/d (mean 6.2 mg/d) for up to 16 weeks
Study: 28847998
Drug: Venetoclax (50-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (50-1200 mg, 800 mg in safety expansion) plus bortezomib and dexamethasone
Study: 28848011
Drug: Ritonavir at
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir at 100 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with ritonavir.
Study: 28848011
Drug: Cobicistat at
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cobicistat at 150 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with cobicistat.
Study: 28848667
Drug: Study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug (specific intervention not mentioned)
Study: 28848672
Drug: IT-139 (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT-139 (625 mg/m)
Study: 28848672
Drug: IT-139 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT-139 (various doses: 20, 40, 80, 160, 320, 420, 500, 625, 780 mg/m)
Study: 28848879
Drug: Twice-Daily Glycopyrrolate
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-Daily Glycopyrrolate
Study: 28850430
Drug: Locally orientated
Normalized name: Papaver orientale seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally orientated treatment for ACNES
Study: 28851316
Drug: ParvOryx (native
Approvals — FDA: no, EMA: no, PMDA: no
Description: ParvOryx (native parvovirus H-1) administered intravenously and intratumorally
Study: 28851415
Drug: Pre-chemotherapy IL-6
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy IL-6 levels
Study: 28851415
Drug: Pre-chemotherapy D-dimer
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy D-dimer levels
Study: 28851423
Drug: PARP inhibitor
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitor veliparib in combination with carboplatin (V-C)
Study: 28851423
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy alone (Control)
Study: 28851978
Drug: Therapy assessed
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy assessed by changes in SOFA score from admission (T1) to 48 hours later (T2)
Study: 28854543
Drug: Dexmedetomidine delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine delivered i.v. by target-controlled infusion